Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

✍ Scribed by Y. Seino; K. W. Min; E. Niemoeller; A. Takami; on behalf of the EFC10887 GETGOAL-L Asia Study Investigators

• Book ID: 118712576
• Publisher: John Wiley and Sons
• Year: 2012
• Tongue: English
• Weight: 602 KB
• Volume: 14
• Category: Article
• ISSN: 1462-8902
• DOI: 10.1111/j.1463-1326.2012.01618.x